KRAS Gene Mutation Associated with Grade of Tumor Budding and Peripheral Immunoinflammatory Indices in Patients with Colorectal Cancer
Liu Liang,Xuemin Guo,Wei Ye,Yuxiang Liu
DOI: https://doi.org/10.2147/ijgm.s487525
IF: 2.145
2024-10-19
International Journal of General Medicine
Abstract:Liu Liang, 1 Xuemin Guo, 1 Wei Ye, 1 Yuxiang Liu 2 1 Department of Laboratory Medicine, Meizhou People's Hospital, Meizhou, People's Republic of China; 2 Department of Medical Oncology, Meizhou People's Hospital, Meizhou, People's Republic of China Correspondence: Liu Liang, Department of Laboratory Medicine, Meizhou People's Hospital, Meizhou, People's Republic of China, Email Background: The efficacy of targeted therapy for colorectal cancer (CRC) is affected by hub genes of epidermal growth factor receptor (EGFR) signaling pathways, such as KRAS . Immune cell infiltration may lead to gene mutation, but the relationship between KRAS status and peripheral immune-inflammatory indices has not been clarified in CRC. Methods: Clinical records of CRC patients were collected. The relationship between KRAS status and clinicopathological characteristics, peripheral immune-inflammatory indices (pan-immune inflammation value (PIV) (monocyte×neutrophil×platelet/lymphocyte), systemic immune inflammation index (SII) (platelet×neutrophil/lymphocyte), and system inflammation response index (SIRI) (monocyte×neutrophil/lymphocyte)) were analyzed. Results: 1033 CRC patients were collected, there were 514 (49.8%) patients with KRAS wild-type and 519 (50.2%) with KRAS mutation. Patients with KRAS mutation had higher proportions of female, III-IV stage, and lymph node metastasis and lower proportion of low grade of tumor budding (the presence of single tumor cells or small clusters of up to 5 cells in mesenchyma at the front of tumor invasion) than those with KRAS wild-type. The PIV, SII, and SIRI levels in KRAS mutation patients were significantly higher than those in KRAS wild-type patients. The proportion of aged ≥ 65 years old, dMMR, distant metastasis, and KRAS mutation were high in patients with high PIV, SII, and SIRI levels. Logistic regression analysis showed that non-low grade of tumor budding (odds ratio (OR): 1.970, 95% confidence interval (CI): 1.287– 3.016, p =0.002), and high SII level (≥ 807.81 vs < 807.81, OR: 1.915, 95% CI: 1.120– 3.272, p =0.018) were independently associated with KRAS mutation. Conclusion: Non-low grade of tumor budding, and high SII level were independently associated with KRAS mutation in CRC. It provides additional references for diagnosis and treatment options for patients with CRC. Keywords: colorectal cancer, KRAS , systemic immune inflammation index, tumor budding Colorectal cancer (CRC) is a cancer that occurs in the gut. 1 According to the statistics by the GLOBOCAN in 2020, the incidence and mortality of CRC in the world rank third and second respectively among malignant tumors. 2 Genetic factors, 3,4 bad diet and lifestyle habits, 5 obesity, 6 and low physical activity, 7 intestinal flora imbalance 8,9 are closely related to the development of CRC. With the rapid development of precision medicine, CRC has entered a targeted therapy mode with gene mutation status as a biomarker. 10 Tyrosine kinase inhibitors (TKI) have shown good efficacy in cancer patients with EGFR-activating mutations. 11 EGFR as one of the main targets of targeted drugs, is a transmembrane tyrosine kinase receptor. The downstream of this signal transduction pathway mainly include RAS/RAF/MAPK, PI3K/AKT/mTOR pathways, and EGFR binding with ligands can cause the activation of the two downstream major pathways, thereby inducing cell proliferation, invasion, metastasis, and angiogenesis. 12 Rat sarcoma (RAS) gene is one of family of human proto-oncogenes, and Kirsten rat sarcoma viral oncogene homologue (KRAS) gene is the most studied RAS gene. 13,14 KRAS mutation leads to the continuous activation of EGFR-dependent RAS/RAF/MAPK pathway, causing excessive cell proliferation and differentiation, and thus inducing the progression of CRC. 15 More than 30% of CRC patients had KRAS gene activating mutations. 16 Immune inflammation is involved in the pathogenesis of many diseases. 17,18 The results of the study on the relationship between inflammatory response and tumor suggest that inflammatory microenvironment may promote the occurrence, development and distant metastasis of tumor. 19,20 Long-term inflammatory stimulation can lead to changes in tumor-related genes, 21 but there are very few studies on the correlation between inflammatory indicators and gene status. The main factors affecting the choice of treatment and prognosis of CRC pati -Abstract Truncated-
medicine, general & internal